[图书][B] Identifying Racial/Ethnic Differences in Clinical Trial Enrollment, Drug Response, and Genetic Biomarkers of Taxane Induced Peripheral Neuropathy in African …
E Shah - 2021 - search.proquest.com
My first aim identified enrollment patterns and variables that predict enrollment in a diverse
underserved population and evaluated barriers to enrollment. We analyzed data from the …
underserved population and evaluated barriers to enrollment. We analyzed data from the …
Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci
LE Sucheston-Campbell, AI Clay-Gilmour… - Pharmacogenetics …, 2018 - journals.lww.com
Objective Taxane containing chemotherapy extends survival for breast cancer patients.
However, taxane-induced peripheral neuropathy (TIPN) cannot be predicted, prevented or …
However, taxane-induced peripheral neuropathy (TIPN) cannot be predicted, prevented or …
[HTML][HTML] CYP2C8* 3 increases risk of neuropathy in breast cancer patients treated with paclitaxel
DL Hertz, S Roy, AA Motsinger-Reif, A Drobish… - Annals of oncology, 2013 - Elsevier
Background Paclitaxel-induced neuropathy is an adverse event that often leads to
therapeutic disruption and patient discomfort. We attempted to replicate a previously …
therapeutic disruption and patient discomfort. We attempted to replicate a previously …
Genetic heterogeneity beyond CYP2C8* 3 does not explain differential sensitivity to paclitaxel-induced neuropathy
The development of paclitaxel-induced peripheral neuropathy (PIPN) is influenced by drug
exposure and patient genetics. The purpose of this analysis was to expand on a previous …
exposure and patient genetics. The purpose of this analysis was to expand on a previous …
A meta-analysis GWAS of taxane-induced peripheral neuropathy in patients with breast cancer.
YJ Yang, KR Schaffer, G Jiang, TC Tran, PJ Sauer… - 2024 - ascopubs.org
12089 Background: Taxane-induced peripheral neuropathy (TIPN) is a common dose-
limiting toxicity in the medical management of breast cancer patients. Despite the clinical …
limiting toxicity in the medical management of breast cancer patients. Despite the clinical …
Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN …
Purpose: Paclitaxel is a widely used anticancer therapeutic. Peripheral neuropathy is the
dose-limiting toxicity and negatively impacts quality of life. Rare germline gene markers …
dose-limiting toxicity and negatively impacts quality of life. Rare germline gene markers …
Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy during paclitaxel treatment.
10515 Background: Peripheral neuropathy is the most common severe toxicity in patients
treated with paclitaxel. Putative genetic mutations in genes relevant to drug metabolism …
treated with paclitaxel. Putative genetic mutations in genes relevant to drug metabolism …
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black …
TJ Ballinger, F Zhao, JA Sparano, SF Garcia, F Shen… - 2024 - ascopubs.org
LBA503 Background: Black women experience higher rates of TIPN compared to White
women when receiving weekly paclitaxel (WP) for early-stage breast cancer. This disparity …
women when receiving weekly paclitaxel (WP) for early-stage breast cancer. This disparity …
Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy
M Apellániz-Ruiz, MY Lee, L Sánchez-Barroso… - Clinical Cancer …, 2015 - AACR
Purpose: Paclitaxel, a widely used chemotherapeutic drug, can cause peripheral
neuropathies leading to dose reductions and treatment suspensions and decreasing the …
neuropathies leading to dose reductions and treatment suspensions and decreasing the …
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast …
BP Schneider, F Zhao, TJ Ballinger… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Black women experience higher rates of taxane-induced peripheral neuropathy
(TIPN) compared with White women when receiving adjuvant once weekly paclitaxel for …
(TIPN) compared with White women when receiving adjuvant once weekly paclitaxel for …
相关搜索
- breast cancer peripheral neuropathy
- ecog acrin peripheral neuropathy
- black women peripheral neuropathy
- breast cancer ecog acrin
- breast cancer black women
- genetic biomarkers trial enrollment
- trial enrollment drug response
- transport genes peripheral neuropathy
- genetic biomarkers drug response
- taxane type peripheral neuropathy
- drug metabolism peripheral neuropathy
- breast cancer taxane type
- meta analysis peripheral neuropathy
- breast cancer meta analysis
- transport genes drug metabolism
- paclitaxel treatment peripheral neuropathy